--- end of press release ---
Key Points:
- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapies.
- “Over the past years we have conscientiously built an extensive international intellectual property portfolio across major markets, which we expect will provide a significant competitive advantage.
- Each technology we design and develop aims to enhance efficacy and mitigate safety risk to the patient and is based on our extensive immunology research and experience.
- We are pleased to receive this latest patent grant for our iM-TCR technology from the European Patent Office, which complements our recently granted patent in Japan,” said Dolores Schendel, CSO at Medigene.
Details on the poster presentation are as follows:
Key Points:
- Details on the poster presentation are as follows:
Session details: PO.IM01.13 - Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T, Sunday, April 7, 1:30 PM - 5:00 PM local time
The work to be presented shows that recombinant T cell receptor engineered T cells (rTCR-T cells), when armored and enhanced by the PD1-41BB CSP, exhibit superior TCR-T cell functionality and safety as well as a favorable safety profile, revealing the strong potential for improving treatment of cancer patients suffering from advanced solid tumor malignancies.
- The Company is planning a first-in-human trial for MDG1015, a TCR-T therapy incorporating the CSP in gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma with IND/CTA filing targeted for 2H 2024.
- MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by the PD1-41BB CSP.
--- end of press release ---
Key Points:
- “We are delighted with the receipt of the patent grant for our iM-TCR from the Japan Patent Office as we continue to expand and strengthen our IP portfolio.
- The ability to control the level of TCR activity with our iM-TCR technology after dosing has the potential to deliver more individualized efficacy and safety for patients.
- This patent grant is further validation of this innovative iM-TCR technology,” said Selwyn Ho, CEO at Medigene.
- The iM-TCR technology modifies the TCR to achieve control of TCR surface expression, allowing for fine-tuning of activity against tumor cells and thereby reducing potential inflammatory responses in the body.
Retrieved on:
Saturday, November 4, 2023
3D,
Gamma ray,
Society for Immunotherapy of Cancer,
TCR,
Prevalence,
Dicarboxylic acid,
KRAS,
CSP,
SITC,
Tissue,
Immunotherapy,
FSE,
Safety,
Society,
Cancer,
Patient,
HLA,
Toxicity,
B cell,
Vaccine Robust co-expression of the recombinant TCRs (rTCRs) and the PD1-41BB CSP was demonstrated for the three TCR candidates.
Key Points:
- Robust co-expression of the recombinant TCRs (rTCRs) and the PD1-41BB CSP was demonstrated for the three TCR candidates.
- These effects were limited to mKRAS G12V-expressing cells, as cancer cells harboring wild-type KRAS were not affected.
- In addition, increased and sustained killing ability of 3D tumor spheroids was detected with the selected TCR candidates, demonstrating the potent cytotoxic activity directed towards cancer cells with mKRAS G12V.
- None of the TCRs recognized HLA allotypes other than HLA-A11 in a panel of cell lines expressing globally common HLA allotypes.
Retrieved on:
Wednesday, September 27, 2023
Planegg,
European patent law,
European Patent Office,
FSE,
EP3,
Patent,
Patient,
European Patent Convention,
CSP,
Safety,
Pharmaceutical industry --- end of press release ---
Key Points:
- Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology.
- Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene.
- “We are delighted to have been granted the European Patent for our PD1-41BB CSP, one of the key technologies of Medigene’s End-to-End (E2E) Platform.
- This complements our PD1-41BB IP-portfolio with similar patents already granted in the United States, China and Japan, and strengthens our patent portfolio worldwide,” said Selwyn Ho, CEO at Medigene AG.
Retrieved on:
Monday, September 18, 2023
KRAS,
Maintenance,
Planegg,
CD28,
Prevalence,
Neoplasm,
FSE,
Toxicity,
TCR,
Incidence,
Patient,
Growth,
Tumor microenvironment,
Kirsten,
CSP,
Vaccine “The selection of this first mKRAS (mutant KRAS) lead TCR further validates our capabilities to generate 3S TCRs across both neoantigens and cancer-testis antigens.
Key Points:
- “The selection of this first mKRAS (mutant KRAS) lead TCR further validates our capabilities to generate 3S TCRs across both neoantigens and cancer-testis antigens.
- One such attribute is the identification of a TCR candidate demonstrating bi-specific recognition for both the KRAS G12V and G12C mutations.
- Directed TCR discovery efforts in the future will enable identification of an optimal KRAS G12C-specific TCR lead.
- Global incidence of solid tumors expressing KRAS mutations is estimated to be in excess of 300,000 patients.
Retrieved on:
Wednesday, August 30, 2023
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors.
Key Points:
- Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors.
- Prof. Dolores Schendel, Medigene‘s Chief Scientific Officer, has been invited to present at the 8th CAR-TCR Summit in Boston on August 30, 2023.
- “Medigene is committed to creating best-in-class, differentiated TCR-T therapies for multiple solid tumor indications that are optimized for both safety and efficacy.
- For more details, please find the presentation on Medigene’s website: https://medigene.com/science/abstracts/
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 7th annual Immuno-Oncology Summit Europe which will take place June 20-22, 2023 in London, UK.
Key Points:
- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 7th annual Immuno-Oncology Summit Europe which will take place June 20-22, 2023 in London, UK.
- The data to be presented provide an overview on the enhanced activity of T cell receptor engineered T cell (TCR-T) therapy seen with the combination of the PD1-41BB switch receptor with T cell receptors (TCRs) specific for different target antigens.
- Irrespective of the target antigen specificity, TCRs combined with the PD1-41BB switch receptor displayed superior T cell functionality in vitro and increased T cell efficacy in vivo as compared to TCR-T cells without the switch receptor (“naked” TCR).
- Details on the oral presentation are as follows:
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will host an R&D Event to discuss the pipeline expansion and the evolution of its end-to-end platform on Tuesday, June 20, 2023, at 10:00 am ET.
Key Points:
- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will host an R&D Event to discuss the pipeline expansion and the evolution of its end-to-end platform on Tuesday, June 20, 2023, at 10:00 am ET.
- A live Q&A session will follow the formal presentations and discussions.
- Attendees are invited to listen to the presentations and discussions exploring the unmet needs in the treatment of solid tumors.
- Full details for the webcast and registration are as follows:
KRAS,
Antigen,
Planegg,
CD28,
Prevalence,
Q&A,
Neoplasm,
FSE,
Incidence,
TCR,
ET,
Patient,
Webcast,
Growth,
Kirsten,
TSA,
Vaccine,
Medical imaging Medigene is building a broad KRAS library consisting of multiple T cell receptors (TCRs) targeting multiple KRAS mutations and multiple HLAs, covering large patient populations suffering from solid tumors with high unmet need
Key Points:
- Medigene is building a broad KRAS library consisting of multiple T cell receptors (TCRs) targeting multiple KRAS mutations and multiple HLAs, covering large patient populations suffering from solid tumors with high unmet need
Management to host an R&D Event to discuss pipeline expansion and evolution of the end-to-end platform on Tuesday, June 20, 2023, at 10:00 am ET
Planegg/Martinsried, June 1, 2023.
- KRAS mutations are widely recognized as the most common oncogene mutations in difficult-to-treat solid tumors existing in ~30% of solid tumors, such as pancreatic, colorectal, endometrial and non-small-cell lung cancer.
- Global incidence of solid tumors expressing KRAS mutations is estimated to be in excess of 300,000 patients.
- “Our pipeline expansion into neoantigens with multiple KRAS targets represents a major advance in our pursuit to develop best-in-class TCR-T therapies for patients suffering from difficult-to-treat solid tumors,” said Dr. Selwyn Ho, Chief Executive Officer at Medigene.
